Camelo-Filho Antonio E, Silva André M S, Estephan Eduardo P, Zambon Antônio A, Mendonça Rodrigo H, Souza Paulo V S, Pinto Wladimir B V R, Oliveira Acary S B, Dangoni-Filho Iron, Pouza Ana F P, Valerio Berenice C O, Zanoteli Edmar
Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Department of Neurology, Faculdade de Medicina Santa Marcelina, São Paulo, Brazil.
Front Neurol. 2020 Sep 11;11:1053. doi: 10.3389/fneur.2020.01053. eCollection 2020.
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
重症肌无力（MG）是一种自身免疫性神经肌肉疾病，可能是重症 COVID-19 的一个危险因素。我们在巴西圣保罗的四家医院对 15 例连续收治的成年 COVID-19 合并 MG 患者进行了一项观察性回顾性研究。大多数因 COVID-19 住院的 MG 患者病情严重：87% 入住重症监护病房，73% 需要机械通气，30% 死亡。使用免疫球蛋白和进行血浆置换术是安全的。免疫抑制治疗似乎与更好的预后相关，因为它可能起到保护作用。
